The headlines arrive years before the clinic. A trial result becomes “a cure.” A city resolution becomes “legal.” Ketamine, esketamine, psilocybin and MDMA get placed in one bright bucket, though they have different evidence, rules and risks.
**The short answer: California does not have legal psilocybin or MDMA therapy. Both remain investigational and federally controlled. Ketamine is a legal prescription drug but is not FDA-approved for a psychiatric condition. Esketamine nasal spray is FDA-approved for specific forms of depression and must be given through a supervised safety program.**¹ ² ³
Four substances, four different answers
| If you are considering… | What is true in California now | The honest route |
|---|---|---|
| Psilocybin | Promising depression trials; not FDA-approved; Schedule I federally | A registered clinical trial, or established depression care while research continues |
| MDMA-assisted therapy | Phase 3 PTSD trials reported benefit, but MDMA is not FDA-approved and remains Schedule I | Established PTSD treatments or a registered clinical trial |
| IV/IM ketamine | Approved as an anesthetic; psychiatric use is off-label | A licensed medical practice that explains monitoring, evidence, alternatives and total cost |
| Esketamine (Spravato) | FDA-approved for treatment-resistant depression, and for depressive symptoms with acute suicidal ideation or behavior under its label | A certified health-care setting; monitoring for at least two hours after each dose |
“Off-label” does not mean illegal or automatically poor care. It means the FDA did not approve that drug for that use. “Investigational” is different again: a research program follows a protocol and consent process; it is not ordinary treatment sold under a futuristic name.
What the psilocybin evidence actually says
Randomized phase 2 trials found reductions in depression scores after one supervised dose with psychological support. They also reported more adverse events, and one treatment-resistant-depression trial did not show a sustained response through 12 weeks on its key sustained measure. Trial participants were screened; common exclusions included histories of psychosis or mania and active suicidal intent.⁴ ⁵
That is a serious signal, not a settled consumer treatment. The FDA issued final trial-design guidance in July 2026 and is accelerating further research. The agency states plainly that allowing a study to proceed or granting a development designation does not mean a drug is approved, safe or effective.¹
“Decriminalized” is not the same as legal treatment
California's statewide decriminalization bill, SB 58, was vetoed in 2023. A local decision to make enforcement a low priority does not create an FDA-approved treatment, a state-licensed service or an exemption from state and federal controlled-substance law.² ³
A California therapist may help you make sense of an experience or discuss risks without supplying or administering an illegal drug. Ask where psychotherapy ends and medical treatment begins, who holds which license, and who is responsible during the drug session. The title “psychedelic facilitator” alone answers none of those questions.
Use this five-question screen
- What exact drug and route are you offering? “Psychedelic” is not an answer.
- Is this FDA-approved, off-label prescribing, or a registered clinical trial? Get one of those three answers.
- Who medically screens and monitors me, and what is that person's license? Verify it independently.
- What happens if I panic, become confused, have high blood pressure or need help afterward? A safety plan should exist before payment.
- What does the evidence show for my diagnosis—and what does it not show? Ask for the trial, not a testimonial.
Do this: if research participation is the route you want, search ClinicalTrials.gov by condition, location and recruiting status. Do not pay someone merely to place you on a “trial waitlist.” If you want depression or PTSD care now, compare the established routes first: depression → · trauma and PTSD →.
Q&A
Q: Is psychedelic therapy legal in California? A: There is no California system of legal psilocybin or MDMA therapy. Those drugs remain investigational and federally controlled. Prescription ketamine may be used off-label by a licensed prescriber, while esketamine has specific FDA-approved depression indications and a mandatory supervised program. A city's enforcement policy does not turn psilocybin into licensed treatment.
Need a therapist for depression, trauma or making sense of a difficult experience? Choose by need, schedule and payment route →
Sources
- FDA, “Psychedelic Drugs” and final guidance for clinical investigations (July 2026) — fda.gov.
- DEA, Psilocybin Drug Fact Sheet and federal Schedule I status — dea.gov (PDF).
- Governor of California, SB 58 veto message (October 7, 2023) — ca.gov (PDF).
- Raison et al., randomized phase 2 psilocybin trial for major depressive disorder, JAMA (2023) — PubMed.
- Goodwin et al., phase 2 psilocybin trial for treatment-resistant depression, New England Journal of Medicine (2022) — PubMed.
- Mitchell et al., randomized phase 3 MDMA-assisted therapy trial for PTSD, Nature Medicine (2023) — PubMed.
Paid for by participating therapists. Inclusion is computed from availability data — never purchased. No ads, no data sold.